BioSpace News Archive

Eitan Medical announced today it has earned International Organization for Standardization (ISO) 14001 certification for the quality management system for production of its range of medical devices including its Sapphire infusion pumps and the Sorrel™ wearable drug delivery platform solution.

Foghorn® Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced management’s participation in the following investor conferences in August.

SeaStar Medical, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO) today announced that SeaStar Medical’s novel Selective Cytopheretic Device (SCD) was successfully used in a pediatric patient with hemophagocytic lymphohistiocytosis (HLH), a dysregulated immune disorder in children associated with Epstein Barr virus (EBV), the virus that causes mononucleosis.

BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of Ottawa Heart Institute, the first Canadian clinical investigational site for the CardiAMP® Cell Therapy Heart Failure Trial.

Ashvattha Therapeutics announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer -based PET tracer, [18F]OP-801, can detect neuroinflammation via activated microglia and macrophages with higher sensitivity than translocator protein 18 kDa [TSPO]-PET, using [18F]GE180, an established and validated PET imaging approach, in a mouse model of Alzheimer’s Disease.

Portage Biotech Inc. today announced financial results for the fiscal year ended March 31, 2022.

Akari Therapeutics, Plc, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announced that it is prioritizing two pipeline programs.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared Armata’s Investigational New Drug (IND) application for AP-SA02 in prosthetic joint infection (PJI).

Sionna Therapeutics, a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), today announced the formation of a Scientific Advisory Board (SAB).

AnHeart Therapeutics (“AnHeart”), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, today announced the appointment of Shuanglian (Lian) Li, M.D., Ph.D., as the company’s Senior Vice President and Chief Medical Officer (US).